Compare DTSS & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTSS | QNRX |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 10.7M |
| IPO Year | 2015 | 2023 |
| Metric | DTSS | QNRX |
|---|---|---|
| Price | $0.84 | $5.91 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 87.6K | 20.8K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $71,616,820.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 198.70 | N/A |
| 52 Week Low | $0.64 | $5.20 |
| 52 Week High | $2.60 | $41.80 |
| Indicator | DTSS | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.12 | 43.31 |
| Support Level | $0.81 | $5.34 |
| Resistance Level | $1.01 | $6.98 |
| Average True Range (ATR) | 0.07 | 0.47 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 13.83 | 47.65 |
Datasea Inc is a technology company that operates in two main segments. The first segment, Acoustic High-Tech, focuses on developing and applying acoustic technologies, such as ultrasound, infrasound, and mechanical wave effects, for applications like ultrasonic sterilization, neuro-regulation, acupoint stimulation, and environmental purification. The second segment, AI Multimodal Digitalization, integrates artificial intelligence with 5G networks and big data processing to create a proprietary multimodal data platform that combines text, voice, image, and video for real-time intelligent analysis and generation. The company generates all of its revenue from the People's Republic of China (PRC).
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.